Antiphospholipid antibodies induce vascular functional changes in mice: A mechanism of vascular lesions in antiphospholipid syndrome?

Lupus

Volumn 17, Issue 3, 2008, Pages 185-194

  Belizna, Cristina ^a,b   Lartigue, A ^a   Favre, J ^a   Gilbert, D ^a   Tron, F ^a   Levesque H ^a,b   Thuillez, C ^a   Richard, V ^a  

^a INSERM   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Antiphospholipid; Atherosclerosis; Vascular functional changes

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PHOSPHOLIPID ANTIBODY; PROSTANOID; ROSUVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPHOSPHOLIPID SYNDROME; ARTERY DIAMETER; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFECT; MALE; MESENTERIC ARTERY; MOUSE; MYOGRAPHY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VASODILATATION;

ACETYLCHOLINE; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODIES, MONOCLONAL; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; ENDOTHELIUM, VASCULAR; FLUOROBENZENES; FREE RADICALS; IMMUNOHISTOCHEMISTRY; MALE; MICE; NITRIC OXIDE; PROSTAGLANDINS; PYRIMIDINES; SULFONAMIDES; VASODILATION;

EID: 42549109578     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307086931     Document Type: Article

References (55)

1. Manzi, S, Meilahn, EN, Rairie, JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-415.
2. Hughes, GR, Harris, NN, Gharavi, AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 486-489.
3. Wilson, WA, Gharavi, AE, Koike, T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
4. Galli, M, Comfurius, P, Maassen, C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547.
5. McNeil, HP, Simpson, RJ, Chesterman, CN, Krilis, SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87: 4120-4124.
6. Vaarala, O, Alfthan, G, Jauhiainen, M, et al. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923-925.
7. Romero, FI, Amengual, O, Atsumi, T, et al. Arterial disease in lupus and secondary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br J Rheumatol 1998; 37: 883-888.
8. Hashimoto, Y, Kawamura, M, Ichikawa, K, et al. Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol 1992; 149: 1063-1068.
9. Hang, LM, Izui, S, Dixon, FJ. (NZW x BXSB)F1 hybrid. A model of acute lupus and coronary vascular disease with myocardial infarction. J Exp Med 1981; 154: 216-221.
10. Yoshida, H, Fujiwara, H, Fujiwara, T, Ikehara, S, Hamashima, Y. Quantitative analysis of myocardial infarction in (NZW x BXSB)F1 hybrid mice with systemic lupus erythematosus and small coronary artery disease. Am J Pathol 1987; 129: 477-485.
11. Yla-Herttuala, S, Palinski, W, Butler, SW, et al. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994; 14: 32-40.
12. Nityanand, S, Bergmark, C, de Faire, U, et al. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J Intern Med 1995; 238: 437-443.
13. Shaw, PX, Goodyear, CS, Chang, MK, Witztum, JL, Silverman, GJ. The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis- associated neo-antigens and apoptotic cells. J Immunol 2003; 170: 6151-6157.
14. Matsuura, E, Koike, T. Accelerated atheroma and anti-beta2-glycoprotein I antibodies. Lupus 2000; 9: 210-216.
15. Shoenfeld, Y, Harats, D, George, J. Atherosclerosis and the antiphospholipid syndrome: a link unravelled? Lupus 1998; 7: S140-S143.
16. Becarevic, M, Andrejevic, S, Bonaci-Nikolic, B, et al. Anti-oxLDL antibodies - marker for arterial thromboses in antiphospholipid syndrome? Clin Lab 2005; 51: 279-283.
17. Matsuura, E, Kobayashi, K, Hurley, BL, Lopez, LR. Atherogenic oxidized low-density lipoprotein/beta2-glycoprotein I (oxLDL/beta2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2006; 15: 478-483.
18. Mizutani, H, Engelman, RW, Kinjoh, K, et al. Prevention and induction of occlusive coronary vascular disease in autoimmune (W/B)F1 mice by haploidentical bone marrow transplantation: possible role for anticardiolipin autoantibodies. Blood 1993; 82: 3091-3097.
19. George, J, Harats, D, Gilburd, B, et al. Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 2000; 102: 1822-1827.
20. Nicolo, D, Goldman, BI, Monestier, M. Reduction of atherosclerosis in low-density lipoprotein receptor-deficient mice by passive administration of antiphospholipid antibody. Arthritis Rheum 2003; 48: 2974-2978.
21. Ameli, S, Hultgardh-Nilsson, A, Regnstrom, J, et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996; 16: 1074-1079.
22. Palinski, W, Miller, E, Witztum, JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A 1995; 92: 821-825.
23. Sherer, Y, Shoenfeld, Y. Antiphospholipid antibodies: are they proatherogenic or an epiphenomenon of atherosclerosis? Immunobiology 2003; 207: 13-16.
24. Nicolo, D, Monestier, M. Antiphospholipid antibodies and atherosclerosis. Clin Immunol 2004; 112: 183-189.
25. Meroni, PL, Parati, G, Tincani, A, Mari, D, Tedesco, F. Inflammatory response and the endothelium. Thromb Res 2004; 114: 329-334.
26. Pierangeli, SS, Espinola, RG, Liu, X, Harris, EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001; 88: 245-250.
27. Kaplanski, G, Cacoub, P, Farnarier, C, et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum 2000; 43: 55-64.
28. Frijns, CJ, Derksen, RH, De Groot, PG, Algra, A, Fijnheer, R. Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus. Clin Exp Immunol 2001; 125: 149-154.
29. Bonetti, PO, Lerman, LO, Lerman, A. Endothelial dysfunction. A marker of atherosclerotic risk. Arterioscler Throm Vasc Biol 2003; 23: 168-175.
30. Wilkinson, IB, Qasem, A, McEniery, CM, et al. Nitric oxide regulates local arterial distensibility in vivo. Circulation 2002; 105: 213-217.
31. Kinlay, S, Creager, MA, Fukumoto, M, et al. Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension 2001; 38: 1049-1053.
32. Mulvany, MJ, Halpern, W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977; 41: 19-26.
33. Richard, V, Kaeffer, N, Tron, C, Thuillez, C. Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and reperfusion. Circulation 1994; 89: 1254-1261.
34. Favre, J, Musette, P, Douin-Echinard, V, et al. Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol 2007; 27: 1064-1067.
35. Gilbert, D, Lopez, B, Parain, J, Koutouzov, S, Tron, F. Overlap of the anti-cardiolipin and anti-nucleosome responses of the (NZW XBXSB)F1 mouse strain: a new pattern of cross-reactivity for lupus-related autoantibodies. Eur J Immunol 2000; 30: 3271-3280.
36. Thebault, S, Gilbert, D, Machour, N, et al. Two-dimensional electrophoresis and mass spectrometry identification of proteins bound by a murine monoclonal anti-cardiolipin antibody: a powerful technique to characterize the cross-reactivity of a single autoantibody. Electrophoresis 2000; 21: 2531-2539.
37. Lartigue, A, Drouot, L, Jouen, F, et al. Association between anti-nucleophosmin and anti-cardiolipin antibodies in (NZW x BXSB)F1 mice and human systemic lupus erythematosus. Arthritis Res Ther 2005; 7: R1394-1403.
38. Li, XZ, McNeilage, LJ, Whittingham, S. Autoantibodies to the major nucleolar phosphoprotein B23 define a novel subset of patients with anticardiolipin antibodies. Arthritis Rheum 1989; 32: 1165-1169.
39. Bonetti, PO, Lerman, LO, Lerman, A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-175.
40. Carreras, LO, Vermylen, JG. "Lupus" anticoagulant and thrombosis - possible role of inhibition of prostacyclin formation. Thromb Haemost 1982; 48: 38-40.
41. Cai, H, Harrison, DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-844.
42. Cines, DB, Pollak, ES, Buck, CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-3561.
43. Laufs, U, La Fata, V, Plutzky, J, Liao, JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135.
44. Essig, M, Nguyen, G, Prie, D, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 1998; 83; 683-690.
45. Meroni, PL, Raschi, E, Camera, M, et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmunity 2000; 15: 237-240.
46. Aprahamian, T, Bonegio, R, Rizzo, J, et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol 2006; 177: 3028-3034.
47. Lawman, S, Mauri, C, Jury, EC, Cook, HT, Ehrenstein, MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 2004; 173: 7641-7646.
48. Ferrara, DE, Liu, X, Espinola, RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003; 48: 3272-3279.
49. Abud-Mendoza, C, de la Fuente, H, Cuevas-Orta, E, et al. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003; 12: 607-11.
50. Dunoyer-Geindre, S, Kruithof, EK, Boehlen, F, et al. Aspirin inhibits endothelial cell activation induced by antiphospholipid antibodies. J Thromb Haemost 2004; 2: 1176-1181.
51. Grosser, N, Schroder, H. Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler Thromb Vasc Biol 2003; 23: 1345-1351.
52. Kopp, E, Ghosh, S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994; 265: 956-959.
53. Pierce, JW, Read, MA, Ding, H, Luscinskas, FW, Collins, T. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol 1996; 156: 3961-3969.
54. Muller, DN, Heissmeyer, V, Dechend, R, et al. Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage. FASEB J 2001; 15: 1822-1824.
55. Leung, MH, Heaton, S, Skan, J, et al. Mortality and malignancy in the multi-ethnic Birmingham Lupus Cohort: aspirin use is beneficial and non-Caucasian origin is not associated with a poor outcome. Rheumatology 2002; 41: S17.